In Tuesday’s trading session, the shares of one of the leading Pharmaceuticals companies in India hits 5 percent upper circuit in the day’s trade after acquisition of land for setting up of a new state-of-the-art Research and Development (R&D) Centre
Price action
With the market capitalization of 711.88 Crores on Tuesday, the shares of Ind-Swift Laboratories Ltd hits 5% upper circuit making a high of Rs 120.48 compared to its previous closing price of Rs 114.75
What happened
Ind-Swift Laboratories Ltd hits 5% upper circuit following the announcement of acquisition of land, which is approximately 4.25 acres located at Village Rampur Sainian, Derabassi, Punjab. The company purchased the land to set up a new, state-of-the-art Research and Development (R&D) Centre for a total cost of Rs. 1.93 Crores.
This land acquisition was purchased from a third-party seller and it does not involve any transactions with the company’s promoters, directors or related parties and the new R&D Centre will be an important step for the company in advancing its research capabilities and enhancing its product development processes.
About the company
Ind-Swift Laboratories Ltd is a leading pharmaceutical company based in India, specializing in the development, manufacturing and marketing of high-quality generic medicines. The company is known for its strong commitment to innovation, research, and customer satisfaction. It includes a wide range of pharmaceutical products across various therapeutic segments, It has established itself as a trusted name in the healthcare industry.
The company focuses on both domestic and international markets, offering products in areas such as cardiovascular, dermatology, oncology, and more. Ind Swift Labs operates state-of-the-art manufacturing facilities, adhering to global quality standards and is committed to research and development to introduce new and improved medicines.
Ind-Swift Laboratories Ltd also places a significant emphasis on sustainability and corporate social responsibility, ensuring that its operations benefit not only its stakeholders but also the communities in which it operates, with continuous innovation and a customer-centric approach the company aims to improve healthcare outcomes worldwide.
Financials
The company’s revenue declined drastically by 95 percent from Rs 289.71 crore in Q2FY24 to Rs 11.96 crore in Q2FY25. Meanwhile, Net profit fell by 98 percent from Rs 31.65 crores to Rs 0.41 crore during the same period.
Key Financial ratios
Ind-Swift Laboratories Ltd has an impressive Return on Equity (RoE) of 10 percent and a Return on Capital Employed (RoCE) of 13 percent and PE ratio of 6.72. Furthermore, the company’s debt-to-equity ratio is 0.02.
Stock Performance
The stock has provided impressive returns of about 30 percent over the last year, along with a 7 percent gain in the past month of 2024, it has continued to perform strongly.
Written by Sridhar
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
